2023
DOI: 10.1038/s41598-022-27301-9
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study

Abstract: Sitagliptin has been suggested as a treatment option for older adults with type 2 diabetes (T2D). However, no randomized controlled trial has been performed to evaluate the efficacy and safety of sitagliptin treatment in older Japanese patients with T2D. The STREAM study was a multicenter, open-label, randomized controlled trial. T2D outpatients aged 65–80 years with moderately controlled glycemic levels (HbA1c 7.4–10.4%) under lifestyle interventions without or with oral anti-diabetic drugs excluding DPP4 inh… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(2 citation statements)
references
References 39 publications
0
1
0
1
Order By: Relevance
“…Dipeptidyl peptidase-4 inhibitors (DPP-4i) could improve glycemic control by preventing the rapid degradation of incretin hormones and inhibiting glucagon secretion [ 7 ]. With a low risk of hypoglycemia and no weight gain, nearly 0.7% reduction in HbA1c was reported when other DPP-4 inhibitors were given either alone or in combination with metformin for the treatment of T2DM patients [ 8 10 ]. Fotagliptin (Salubris Pharmaceuticals, Shenzhen, China) is a selective, once-daily, novel DPP-4 inhibitor approved for glycemic management of T2DM.…”
Section: Introductionmentioning
confidence: 99%
“…Dipeptidyl peptidase-4 inhibitors (DPP-4i) could improve glycemic control by preventing the rapid degradation of incretin hormones and inhibiting glucagon secretion [ 7 ]. With a low risk of hypoglycemia and no weight gain, nearly 0.7% reduction in HbA1c was reported when other DPP-4 inhibitors were given either alone or in combination with metformin for the treatment of T2DM patients [ 8 10 ]. Fotagliptin (Salubris Pharmaceuticals, Shenzhen, China) is a selective, once-daily, novel DPP-4 inhibitor approved for glycemic management of T2DM.…”
Section: Introductionmentioning
confidence: 99%
“…Ситаглиптин активно изучался у пациентов пожилого возраста. По результатам одного из недавних мультицентровых рандомизированных исследований, добавление ситаглиптина позволяло достигать целевого значения HbA 1c <7,4% у 69,4% пациентов через 6 мес лечения, что значимо больше, чем при добавлении плацебо [32]. Важно отметить, что назначение ситаглиптина в этой группе не сопровождалось увеличением числа нежелательных явлений.…”
unclassified